Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status and Forecast 2020-2026

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
Market Analysis and Insights: Global Clinical Oncology Next Generation Sequencing (NGS) Market
In 2019, the global Clinical Oncology Next Generation Sequencing (NGS) market size was US$ 704.7 million and it is expected to reach US$ 1429.7 million by the end of 2026, with a CAGR of 10.6% during 2021-2026.
Global Clinical Oncology Next Generation Sequencing (NGS) Scope and Market Size
Clinical Oncology Next Generation Sequencing (NGS) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Clinical Oncology Next Generation Sequencing (NGS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Clinical Oncology Next Generation Sequencing (NGS) market is segmented into NGS Pre-Sequencing, Sequencing, NGS Data Analysis, Primary, Secondary & Tertiary Data Analysis, etc.
Segment by Application, the Clinical Oncology Next Generation Sequencing (NGS) market is segmented into Academic & Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, etc.
Regional and Country-level Analysis
The Clinical Oncology Next Generation Sequencing (NGS) market is analysed and market size information is provided by regions (countries).
The key regions covered in the Clinical Oncology Next Generation Sequencing (NGS) market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Clinical Oncology Next Generation Sequencing (NGS) Market Share Analysis
Clinical Oncology Next Generation Sequencing (NGS) market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Clinical Oncology Next Generation Sequencing (NGS) business, the date to enter into the Clinical Oncology Next Generation Sequencing (NGS) market, Clinical Oncology Next Generation Sequencing (NGS) product introduction, recent developments, etc.
The major vendors include Illumina, Roche, Agilent Technologies, Knome, Genomatix Software, GATC Biotech, Oxford Nanopore Technologies, Macrogen, Life Technologies, DNASTAR, Exosome Diagnostics, Biomatters, CLC Bio, BGI, Qiagen, Perkin Elmer, Pacific Bioscience, Partek, GnuBIO, Foundation Medicine, Paradigm, Caris Life Sciences, Myriad Genetics, etc.

This report focuses on the global Clinical Oncology Next Generation Sequencing (NGS) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Clinical Oncology Next Generation Sequencing (NGS) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics

Market segment by Type, the product can be split into

NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis

Market segment by Application, split into

Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Clinical Oncology Next Generation Sequencing (NGS) status, future forecast, growth opportunity, key market and key players.
To present the Clinical Oncology Next Generation Sequencing (NGS) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Clinical Oncology Next Generation Sequencing (NGS) are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions